Outsourcing Pharma Editorial Calendar 2024 & 2025 WilliamReed.

Yearly Overview 2024

JANUARY

- Special Edition:
 Focus On Data Management
- 24 Pre-Show: SCOPE Summit

FEBRUARY

Editorial Webinar:
Innovations In Drug
Delivery

MARCH

Special Edition:
Decentralized Clinical Trial
Outlook

APRIL

17 Pre-Show: CPHI North America

MAY

15 Pre-Show: BIO 2024

JUNE

- 05 Pre-Show: DIA 60th Anniversary Special
- Editorial Webinar:

 Diversity: Increasing Trial
 Inclusivity

JULY

Special Edition: Pharma Manufacturing Solutions

AUGUST

Special Edition:
Track And Trace

SEPTEMBER

Special Edition: Data
Management And RBQM

OCTOBER

- O9 Special Edition:
 Precision Medicine
- Editorial Webinar: Psychedelics

NOVEMBER

Special Edition: Decentralized Trial Technology

DECEMBER


Special Edition: API And Excipient Advancements







Yearly Overview 2025



2024

JANUARY

10

SPECIAL EDITION: FOCUS ON DATA MANAGEMENT

Data collection, analysis, and sharing technologies are evolving at a rapid pace, but not every advanced solution fits every organization or project. This special coverage will look at recent advancements and how to determine which tools are the best for a particular job.

24

PRE-SHOW: SCOPE SUMMIT

FEBRUARY

EDITORIAL WEBINAR: INNOVATIONS IN DRUG DELIVERY

28

Innovations in drug delivery never stop and constant progress continues way past the oral route with the development of implants, patches, syringes as well as solutions for transdermal, topical, and oral drug delivery systems that target diseases, provide pain management, address skin conditions, and are used as gastrointestinal aids.

These varying solutions for drug delivery applications are in higher demand than ever because of the aging population, an increase in chronic disease, and patients' increased access to safe and convenient care. This webinar will hear from experts and what their thoughts are on the ever-evolving market and any successes or learning they would like to share.

MARCH

SPECIAL EDITION: **DECENTRALIZED CLINICAL TRIAL OUTLOOK**

13

Decentralized trial adoption continues to increase as technology evolves and lessons are learned about data collection, wearables, patient engagement strategies, and more. Hear more about what industry experts are thinking around DCTs in this special edition.







APRIL

17

PRE-SHOW: CPHI NORTH AMERICA

MAY

15

PRE-SHOW: BIO INTERNATIONAL CONVENTION

JUNE

05

PRE-SHOW: DIA ANNUAL MEETING

13

EDITORIAL WEBINAR: **DIVERSITY: INCREASING TRIAL INCLUSIVITY**

FDA guidance about improving diversity in studies has gained momentum and continues to do so. It has always been a goal of nearly every clinical research professional, but achieving it has been historically difficult, how has this changed since the guidance was issued. This webinar will discuss some of major changes but also the key obstacles that still stand in the way.

JULY

SPECIAL EDITION: PHARMA MANUFACTURING SOLUTIONS

10

With pharmaceutical companies having to carefully reconsider their long-term decisions in procurement, manufacturing, and supply chain while considering factors like the COVID-19 pandemic, inflation, geopolitics, new therapeutic modalities, and new ways of working - things were once disintegrated, fragmented, and disconnected. This newsletter will look at how companies are addressing this differently for them to become automated, intelligent, and connected.







AUGUST

14

SPECIAL EDITION: TRACK AND TRACE

Pharmaceutical track and trace is a combination of records, systems, and processes that enable manufacturers to ensure that their products are securely tracked from the manufacturing plant, through distribution, and onto the pharmacy shelf. This process is critical for the safe and effective distribution of pharmaceutical products to consumers. The special newsletter will look at the track and trace systems in place, so the companies can quickly respond to any recalls or outbreaks and ensure the products they are providing meet all necessary regulations.

SEPTEMBER

11

SPECIAL EDITION: DATA MANAGEMENT AND RBQM

The FDA has issues two sets of guidelines for risk-based quality management which by the middle of 2023, was starting to cause some companies to rethink their approach while others were still showing resistance. Intelligent, informed data management can greatly elevate the efficiency and effectiveness of clinical trials. This newsletter will look at what has happened since along with the latest guidelines and how companies have implemented them - and the impact they have had on patients.

OCTOBER

09

SPECIAL EDITION: **DECENTRALIZED TRIAL TECHNOLOGY**

What are the future trends in precision medicine? Next-generation sequencing technologies are at the forefront of the precision medicine movement. This special edition will dive into what is driving the next wave of precision medicine are multi-omic technologies, which initially focused on genomic and proteomic analysis but now include transcriptomics, metabolomics, epigenomics, microbiomics and phenomics.

09

EDITORIAL WEBINAR: PSYCHEDELICS

In a sign of shifting attitudes, the FDA has released draft guidance to facilitate the development of psychedelic drugs. The FDA says this is an emerging area of drug development. There has been a lot of noise about psychedelics in recent years with more and more clinical trials starting to appear. Could this be the way forward for treating several mental and physical symptoms. This webinar will focus on the changing landscape, small molecule trials and find out who is branching out in this area.







NOVEMBER

13

SPECIAL EDITION: DECENTRALIZED TRIAL TECHNOLOGY

Decentralized trials were highlighted by the pandemic. They have since become more of a necessity. The content of this special edition will look at how trial teams are continuing to make the switch from onsite to virtual, using wearables, telehealth technology, remote monitoring solutions, and the impact AI is having on this.

DECEMBER

11

SPECIAL EDITION: API AND EXCIPIENT ADVANCEMENTS

Active pharmaceutical ingredients (APIs) treat the conditions patients suffer from; excipients also are vital, because they can achieve the characteristics that make the treatments smaller, better textured, and easier to take. This special edition will share the latest advancements, new products, regulatory considerations, and other interesting developments.

2025

JANUARY

15

PRE-SHOW: SCOPE SUMMIT

FEBRUARY

12

SPECIAL EDITION: **DIGITAL HEALTH**

Diagnostic tools and more sophisticated remote- and self-care models have an increasingly important role to play in the pharma world, with advances being seen to deliver some excellent outcomes and a better patient experience. Could augmented reality (AR) be making its way into the pharma world by showing patients how a drug works in 3D - and nurses are already using vein scanners. This special newsletter will explore all the very latest developments in digital health and how pharma innovations are reaching patients.







FEBRUARY

19

EDITORIAL WEBINAR: ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

With many believing that AI and ML have the potential to increase the likelihood of success in drug development by bringing in big changes and improvements in multiple areas of R&D, the impact of the pandemic on clinical trial execution will potentially accelerate the use of AI and ML in clinical trial execution due to an increased reliance on digital technology for data collection and site monitoring. This webinar will gather experts on the very latest developments and discuss the positives and negatives of AI and ML and the impact it is having on patients and where the 'human touch' fits in.

MARCH

12

SPECIAL EDITION: DRUG DELIVERY

Drug delivery systems enable the targeted delivery or controlled release of a pharmaceutical drug into the body. Recent advancements in drug administration techniques have made therapeutic delivery safer and more efficient. This special newsletter will explore the latest systems and any issues still affecting this part of the industry.

APRIL

tbc

SPECIAL EDITION: RARE AND ORPHAN DISEASES

Rare diseases are classified as any disease that affects less than 200,000 Americans. Orphan diseases, including rare diseases, are neglected conditions whose treatments are often not considered profitable due to their cost to develop and limited patient population. This special newsletter will concentrate on the latest advancements for treatment and the financial implications.



